pertussisrokotus

Pertussisrokotus refers to the vaccination against pertussis, commonly known as whooping cough. Pertussis is a highly contagious respiratory infection caused by Bordetella pertussis, which can be particularly serious in young infants. Vaccination aims to prevent disease and reduce transmission in the community.

Most pertussis vaccines are combined with diphtheria and tetanus vaccines, forming DTaP for children and Tdap for older individuals and adolescents. In many countries, a routine vaccination schedule includes several doses in infancy (often around 2, 4, and 6 months), with booster shots in early childhood (around 4–6 years) and again during adolescence. Many programs also recommend a Tdap booster for adults every 10 years and a Tdap dose during pregnancy to protect newborns through maternal antibodies.

Vaccine effectiveness varies by age and time since vaccination. A full primary series substantially lowers the risk of symptomatic pertussis and, when disease occurs, can lessen its severity and duration. Immunity wanes over time, which is why boosters are recommended. While vaccination does not guarantee complete protection from infection, it is a crucial tool for preventing severe illness and reducing hospitalizations, especially among infants who are most at risk.

Safety profiles of acellular pertussis vaccines are well established; common side effects include mild local reactions or fever. Severe adverse events are rare. Contraindications include a history of severe allergic reaction to a previous dose or to any component of the vaccine, and certain moderate or severe illnesses at the time of vaccination.

Pertussisrokotus is a standard part of many national immunization programs and is considered essential for protecting vulnerable populations and controlling pertussis outbreaks.